Sydney School of Public Health, The University of Sydney, Sydney, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.
Trials. 2021 Sep 9;22(1):612. doi: 10.1186/s13063-021-05574-1.
Globally, over 1.2 million people die from chronic kidney disease (CKD) every year. Patients with CKD are up to 10 times more likely to die prematurely than progress to kidney failure requiring kidney replacement therapy. The burden of symptoms and impaired quality of life in CKD may be compounded by comorbidities and treatment side effects. However, patient-important outcomes remain inconsistently and infrequently reported in trials in patients with CKD, which can limit evidence-informed decision-making. The Standardised Outcomes in Nephrology - Chronic Kidney Disease (SONG-CKD) aims to establish a consensus-based core outcome set for trials in patients with CKD not yet requiring kidney replacement therapy to ensure outcomes of relevance to patients, caregivers and health professionals are consistently reported in trials.
SONG-CKD involves four phases: a systematic review to identify outcomes (domains and measures) that have been reported in randomised controlled trials involving adults with CKD who do not require kidney replacement therapy; stakeholder key informant interviews with health professionals involved in the care of adults with CKD to ascertain their views on establishing core outcomes in CKD; an international two-round online Delphi survey with patients, caregivers, clinicians, researchers, policy makers and industry representatives to obtain consensus on critically important outcome domains; and stakeholder consensus workshops to review and finalise the set of core outcome domains for trials in CKD.
Establishing a core outcome set to be reported in trials in patients with CKD will enhance the relevance, transparency and impact of research to improve the lives of people with CKD.
Not applicable. This study is registered with the Core Outcome Measures in Effectiveness Trials (COMET) database: http://www.comet-initiative.org/Studies/Details/1653 .
全球每年有超过 120 万人死于慢性肾脏病(CKD)。CKD 患者的过早死亡率比进展为需要肾脏替代治疗的肾衰竭高出 10 倍。CKD 患者的症状负担和生活质量受损可能因合并症和治疗副作用而加重。然而,在 CKD 患者的试验中,患者重要结局的报告仍然不一致且不频繁,这可能限制了循证决策。肾脏病标准化结局 - 慢性肾脏病(SONG-CKD)旨在为尚未需要肾脏替代治疗的 CKD 患者的试验建立一个基于共识的核心结局集,以确保试验中始终报告与患者、护理人员和卫生专业人员相关的结局。
SONG-CKD 包括四个阶段:系统评价,以确定在不需要肾脏替代治疗的成人 CKD 患者中进行的随机对照试验中已经报告的结局(领域和措施);与参与成人 CKD 护理的卫生专业人员进行利益攸关者关键信息访谈,以确定他们对在 CKD 中建立核心结局的看法;一项国际两轮在线 Delphi 调查,患者、护理人员、临床医生、研究人员、政策制定者和行业代表参与,以就关键重要结局领域达成共识;以及利益攸关者共识研讨会,以审查和最终确定 CKD 试验的核心结局领域集。
建立一个在 CKD 患者试验中报告的核心结局集,将提高研究的相关性、透明度和影响力,从而改善 CKD 患者的生活。
不适用。本研究在疗效试验核心结局测量(COMET)数据库中注册:http://www.comet-initiative.org/Studies/Details/1653。